Clinical Trials

203 enrolled 43 charts

B-cell Malignancies

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

62 enrolled

Lymphoma, Recurrence

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

60 enrolled 20 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02612311 2024-12-13

UNITY-CLL

Phase 3 Terminated

603 enrolled 17 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05219513 2024-08-23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

53 enrolled

Lymphoma, Non-Hodgkin

NCT03866239 2024-08-09

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

47 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

72 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

98 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT02391545 2023-09-28

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

55 enrolled 13 charts

Lymphoma, Follicular

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

3 enrolled

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

29 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

87 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02336048 2021-04-08

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

38 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03539484 2020-09-03

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

26 enrolled 30 charts

Other solid neoplasm

Solid Tumors

NCT02624986 2020-05-18

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

25 enrolled 21 charts

Lymphoma, Non-Hodgkin

NCT01287741 2019-04-12

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Phase 3 Terminated

1,418 enrolled 20 charts

Lymphoma, Large B-Cell, Diffuse

NCT01980875 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Terminated

57 enrolled 12 charts